Form 4: Ultragenyx Executive Thomas Kassberg Reports Stock Transactions
SEC Form 4 Filing
Thomas Kassberg, CBO & EVP of Ultragenyx Pharmaceutical Inc., reports acquisition and disposal of company stock related to performance stock units and tax withholdings.
Summary
- On March 1, 2025, Thomas Kassberg acquired 18,443 shares of Ultragenyx common stock upon conversion of performance stock units.
- On March 3, 2025, Kassberg sold 6,028 shares at an average price of $42.1 to cover tax withholdings related to vesting RSUs.
- Also on March 3, 2025, 508 shares were surrendered to Ultragenyx to cover tax withholdings due to the vesting of RSUs.
- Following these transactions, Kassberg beneficially owns 264,730 shares of Ultragenyx common stock, including shares underlying previously reported RSUs.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
Form 4 filings are standard disclosures required by the SEC for corporate insiders, providing transparency into their trading activities and potential alignment with company performance.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership by a company executive.
Key Dates
| Date | Description |
|---|---|
| 03/01/2025 | Conversion of performance stock units into 18,443 shares of common stock. |
| 03/03/2025 | Sale of 6,028 shares at an average price of $42.1 and surrender of 508 shares to cover tax withholdings. |
| 03/04/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.